Results 81 to 90 of about 9,108 (216)

Ankilozan Spondilit Hastalarında Yaşam Kalitesini ve Fonksiyonel Durumu Hangi Faktörler Etkiler?

open access: yesAnkara Medical Journal, 2017
Giriş: Bu çalışma, Ankilozan spondilit (AS) hastalarında fonksiyonel durumu ve yaşam kalitesini etkileyen olası faktörleri belirlemek amacıyla yapıldı.Materyal ve Metot: Çalışmaya AS'li toplam 88 adet gönüllü Türk hasta dahil edildi.
Gülcan Gürer   +4 more
doaj   +1 more source

Evaluation of Myeloperoxidase/Paraoxonase‐1 Ratio and Dysfunctional HDL Levels in Ankylosing Spondylitis and Their Relationship With Coronary Artery Disease

open access: yesInternational Journal of Clinical Practice, Volume 2026, Issue 1, 2026.
Objectives To determine the level of dysfunctional high‐density lipoprotein (dHDL) with the myeloperoxidase/paraoxonase‐1 (MPO/PON‐1) ratio and its relationship with epicardial adipose tissue thickness (EATT) in patients with ankylosing spondylitis (AS).
Yagmur Cagla Reis Altan   +5 more
wiley   +1 more source

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. [PDF]

open access: yes, 2017
Few studies have investigated the impact of obesity on the response to tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA).
Adrian Ciurea   +11 more
core   +5 more sources

Effect of Nonsteroidal Anti‐Inflammatory Drugs on Sacroiliac Joint Inflammation, as Seen on Magnetic Resonance Imaging, in Axial Spondyloarthritis

open access: yesArthritis Care &Research, Volume 77, Issue 12, Page 1443-1452, December 2025.
Objective Imaging evidence of active sacroiliitis is important for diagnosis, classification, and monitoring of axial spondyloarthritis (axSpA). However, there is no consistent guidance on whether patients should temporarily stop nonsteroidal anti‐inflammatory drugs (NSAIDs) before magnetic resonance imaging (MRI).
Gareth T. Jones   +10 more
wiley   +1 more source

Work outcome in yet undiagnosed patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis; results of a cross-sectional study among patients with chronic low back pain [PDF]

open access: yes, 2017
Background: To understand the impact of yet undiagnosed non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) on work outcomes in a cohort of patients with long-lasting chronic low back pain (CLBP).
Boonen, A.E.R.C.H. (Annelies E.R.C.H.)   +3 more
core   +1 more source

Longitudinal Numbers-Needed-To-Treat (NNT) for Achieving Various Levels of Analgesic Response and Improvement with Etoricoxib, Naproxen, and Placebo in Ankylosing Spondylitis [PDF]

open access: yes, 2011
Background Clinical analgesic trials typically report response as group mean results. However, research has shown that few patients are average and most have responses at the extremes.
Paul M Peloso   +4 more
core   +2 more sources

Effects on Serum Protein Levels From One Bout of High Intensity Interval Training in Individuals With Axial Spondyloarthritis and Controls

open access: yesImmunity, Inflammation and Disease, Volume 13, Issue 12, December 2025.
ABSTRACT Background Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the axial skeleton causing pain, inflammation, and stiffness. Individuals with axSpA are at greater risk of developing cardiovascular disease, which can be counteracted by physical activity. High‐intensity interval training (HIIT) has been shown to
Åsa Andersson   +4 more
wiley   +1 more source

results from the German Spondyloarthritis Inception Cohort [PDF]

open access: yes, 2017
Background Functional status and spinal mobility in patients with axial spondyloarthritis (axSpA) are known to be determined both by disease activity and by structural damage in the spine. The impact of structural damage in the sacroiliac joints (SIJ) on
Haibel, Hildrun   +5 more
core   +1 more source

Effectiveness of Bimekizumab in Psoriatic Arthritis: A Multicenter Real‐Life Study With Clinical and Ultrasound Evaluation in the Lazio Region, Italy

open access: yesInternational Journal of Dermatology, Volume 64, Issue 11, Page 2038-2044, November 2025.
ABSTRACT Background Bimekizumab, a monoclonal antibody targeting interleukin (IL)‐17A and IL‐17F, has shown efficacy in psoriatic arthritis (PsA) clinical trials, but real‐world data on its effectiveness are limited. This study aimed to evaluate its real‐world effectiveness in PsA patients treated in dermatologic settings.
Giacomo Caldarola   +12 more
wiley   +1 more source

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies

open access: yesArthritis Research & Therapy, 2023
Background The objective of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in psoriatic arthritis (PsA) patients with axial involvement.
Xenofon Baraliakos   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy